Opening of BK channels alters cerebral hemodynamic and causes headache in healthy volunteers.

Josefin Snellman, Mohammad Al-Mahdi Al-Karagholi, Hashmat Ghanizada, Jakob Møller Hansen, Messoud Ashina, Cherie Amalie Waldorff Nielsen, Camilla Skandarioon, Cristina Lopez Lopez

Journal: Cephalalgia : an international journal of headache 2021;40(11):1145-1154

PMID: 32847403

Abstract

INTRODUCTION

Preclinical data implicate large conductance calcium-activated potassium (BK) channels in the pathogenesis of headache and migraine, but the exact role of these channels is still unknown. Here, we investigated whether opening of BK channels would cause headache and vascular effects in healthy volunteers.

METHODS

In a randomized, double-blind, placebo-controlled, cross-over study, 21 healthy volunteers aged 18-39 years were randomly allocated to receive an intravenous infusion of 0.05 mg/min BK channel opener MaxiPost and placebo on two different days. The primary endpoints were the difference in incidence of headache and the difference in area under the curve (AUC) for headache intensity scores (0-12 hours) and for middle cerebral artery blood flow velocity (V) (0-2 hours) between MaxiPost and placebo. The secondary endpoints were the differences in area under the curve for superficial temporal artery and radial artery diameter (0-2 hours) between MaxiPost and placebo.

RESULTS

Twenty participants completed the study. Eighteen participants (90%) developed headache after MaxiPost compared with six (30%) after placebo ( = 0.0005); the difference of incidence is 60% (95% confidence interval 36-84%). The area under the curve for headache intensity (AUC,  = 0.0003), for mean V (AUC,  = 0.0001), for superficial temporal artery diameter (AUC,  = 0.003), and for radial artery diameter (AUC,  = 0.03) were significantly larger after MaxiPost compared to placebo.

CONCLUSION

MaxiPost caused headache and dilation in extra- and intracerebral arteries. Our findings suggest a possible role of BK channels in headache pathophysiology in humans. ClinicalTrials.gov, ID: NCT03887325.

Address: Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.; Novartis Pharma AG, Basel, Switzerland.; Danish Headache Knowledge Center, Rigshospitalet Glostrup, Glostrup, Denmark.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.